Eli Lilly and Company (NYSE:LLY) Shares Acquired Rep. David Taylor

Key Points

• Representative David Taylor purchased shares of Eli Lilly and Company (NYSE:LLY) between $1,001 and $15,000 on August 14th, 2025.
• Eli Lilly recently reported earnings of $6.31 per share for the quarter, exceeding estimates, with revenue at $15.56 billion, a 37.6% increase year-over-year.
• The company announced a quarterly dividend of $1.50 per share, scheduled for payment to shareholders on September 10th, representing a 0.8% yield.

Representative David Taylor (R-Ohio) recently bought shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on September 02nd, the Representative disclosed that they had bought between $1,001 and $15,000 in Eli Lilly and Company stock on August 14th. The trade occurred in the Representative's "DAVID TAYLOR TRUST > SCHWAB JOINT BROKERAGE #1 (HOME GROWN)" account.

Representative David Taylor also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Marathon Petroleum NYSE: MPC on 8/14/2025.
• Purchased $15,001 - $50,000 in shares of Eli Lilly and Company NYSE: LLY on 8/14/2025.
• Purchased $1,001 - $15,000 in shares of Prologis NYSE: PLD on 8/14/2025.
• Purchased $1,001 - $15,000 in shares of Visa NYSE: V on 8/13/2025.
• Purchased $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 8/13/2025.
• Sold $1,001 - $15,000 in shares of Installed Building Products NYSE: IBP on 8/13/2025.
• Purchased $1,001 - $15,000 in shares of Prologis NYSE: PLD on 8/7/2025.
• Purchased $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 8/7/2025.
• Purchased $1,001 - $15,000 in shares of Vertex Pharmaceuticals NASDAQ: VRTX on 8/7/2025.
• Sold $1,001 - $15,000 in shares of Installed Building Products NYSE: IBP on 8/7/2025.

Eli Lilly and Company Price Performance

Shares of LLY traded up $4.39 on Thursday, reaching $742.22. The stock had a trading volume of 2,419,935 shares, compared to its average volume of 4,141,353. The firm has a 50-day moving average of $745.91 and a 200 day moving average of $783.42. The firm has a market capitalization of $702.48 billion, a PE ratio of 48.51, a PEG ratio of 1.02 and a beta of 0.47. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $943.00. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the previous year, the company posted $3.92 EPS. The business's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company's payout ratio is 39.22%.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. PNC Financial Services Group Inc. grew its holdings in shares of Eli Lilly and Company by 97.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock worth $83,669,349,000 after purchasing an additional 50,002,551 shares during the period. Vanguard Group Inc. increased its position in shares of Eli Lilly and Company by 1.5% in the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company's stock worth $62,680,004,000 after acquiring an additional 1,183,038 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Eli Lilly and Company by 103,831.6% in the 1st quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock valued at $12,278,292,000 after acquiring an additional 14,852,076 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Eli Lilly and Company by 0.6% during the 1st quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company's stock valued at $10,495,261,000 after acquiring an additional 81,587 shares in the last quarter. Finally, Laurel Wealth Advisors LLC boosted its position in Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company's stock worth $9,005,392,000 after purchasing an additional 11,537,661 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Eli Lilly and Company

In related news, EVP Daniel Skovronsky bought 1,000 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Gabrielle Sulzberger purchased 117 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director owned 2,703 shares in the company, valued at $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 4,514 shares of company stock valued at $2,894,841 over the last 90 days. Corporate insiders own 0.14% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on LLY shares. Daiwa America cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. Hsbc Global Res upgraded Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a report on Wednesday, August 27th. Cantor Fitzgerald dropped their price target on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a research report on Wednesday, August 13th. Deutsche Bank Aktiengesellschaft reduced their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Finally, Guggenheim decreased their price objective on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research note on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus price target of $950.17.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio's 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Taylor (Republican Party) ran for election to the U.S. House to represent Ohio's 2nd Congressional District. He won in the general election on November 5, 2024. David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor's career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.